| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Analytical Bio-Chemistry (ABC) Laboratories, Inc. is a GLP and CGMP-compliant contract laboratory with expertise in analytical services and radiolabeling synthesis. From its inception in 1968, ABC Laboratories has been dedicated to solving scientific
At Precision for Medicine, we help our pharmaceutical and life sciences clients innovate, develop, and commercialize next generation medical products. Backed by a diverse team of experts across the spectrum of the healthcare marketplace, we provide a comprehensive and integrated set of services that help accelerate research, enable market adoption, enhance patient outcomes, and realize the full commercial potential of new therapies and products.
TWG Market Research is a Barrington, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AustarPharma, LLC is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.